Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average) (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $179.8 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $179.8 million, up 6.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $179.8 million (up 6.27% YoY), and the FY2025 annual result was $171.6 million, up 20.1% from the prior year.
• Shares Outstanding (Weighted Average) improved to $179.8 million in Q1 2026 per RLAY's latest filing, from $171.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $179.8 million in Q1 2026 and troughed at $108.3 million in Q1 2022.
• A 5-year average of $137.4 million and a median of $130.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) grew 29.91% in 2025, then grew 6.27% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $112.2 million in 2022, then grew by 9.22% to $122.6 million in 2023, then advanced by 16.55% to $142.9 million in 2024, then rose by 20.1% to $171.6 million in 2025, then climbed by 4.82% to $179.8 million in 2026.
• Business Quant data shows RLAY's Shares Outstanding (Weighted Average) at $179.8 million in Q1 2026, $171.6 million in Q4 2025, and $172.4 million in Q3 2025.